The pres, does mention it
"Sozinibercept is being developed for use in combination with any of the existing anti-VEGF-A agents, biosimilars, or novel therapies in development for wAMD...The $15bn global market comprised of Eylea, Vabysmo, Lucentis revenue plus an estimate for biosimilars, Avastin off-label, and Beovu of ~$1bn"
Ann: Trading Halt, page-119
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
43.0¢ |
Change
0.015(3.61%) |
Mkt cap ! $529.3M | |||
| Open | High | Low | Value | Volume |
| 42.0¢ | 44.0¢ | 40.5¢ | $679.0K | 1.610M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2499 | 43.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 44.0¢ | 61452 | 2 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| OPT (ASX) Chart |